Ibrutinib significantly outperformed ofatumumab as a second-line therapy for the treatment of relapsed chronic lymphocytic leukemia (CLL) in a head-to-head comparison of two Food and Drug Administration-approved drugs. This was a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. Ibrutinib (Imbruvica) is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1mFXqZk
No comments:
Post a Comment